Theranostics is an emerging field in nuclear medicine that combines therapy and diagnostics using radiopharmaceuticals. This approach allows for personalized treatment, where the same molecule used for imaging is also employed for delivering targeted therapy. Examples include Lutetium-177 DOTATATE for neuroendocrine tumors and Lutetium-177 PSMA therapy for prostate cancer. By identifying and targeting specific receptors, theranostics minimizes damage to healthy tissues while maximizing treatment efficacy. The precision offered by this approach has transformed cancer care, improving survival rates and quality of life for patients. As research progresses, theranostics is set to redefine how complex diseases are diagnosed and treated.
Read more: The Role of Artificial Intelligence in Nuclear Medicine